Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMX0035 in progressive supranuclear palsy
NL-OMON59854Phase 3Completed
- Sponsor
- Amylyx Pharmaceuticals
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sodium phenylbutyrate in progressive supranuclear palsy (PSP) (2 arms), sponsored by Amylyx Pharmaceuticals. Primary endpoints: Change from baseline at Week 52 in total PSPRS score and Change from baseline at Week 52 in 10-item PSPRS score. Started Apr 2024; status: completed.
02
Drugs
sodium phenylbutyrate
03
Conditions
progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on NL-OMON59854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59854.